Table 3.
List of clinical trials of epigenetic combination therapies in cancer treatment.
| Epigenetic therapy | Other therapy | Phase | Cancer type | Primary outcome measures | Clinical trial |
|---|---|---|---|---|---|
| Azacitidine | Ivosidenib | Phase III | Mutant-IDH1 acute myeloid leukemia | OS EFS |
NCT03173248 |
| Azacitidine | Enasidenib | Phase I/II | Mutant-IDH2 acute myeloid leukaemia | OS ORR |
NCT02677922 NCT03683433 |
| Azacitidine Decitabine | Venetoclax | Phase I | Acute myeloid leukaemia | OS MTD ORR |
NCT02203773 NCT02993523 |
| Azacitidine | Gilteritinib | Phase III | Acute myeloid leukemia | OS | NCT02752035 |
| Azacitidine | Pembrolizumab | Phase II | Metastatic colorectal cancer Myelodysplastic syndrome |
OS ORR PFS |
NCT02260440 NCT03094637 |
| Guadecitabine | Carboplatin | Phase II | Ovarian Cancer | OS PFS |
NCT01696032 |
| Azacitidine | Avelumab | Phase I/II | Acute myeloid leukemia | OS ORR |
NCT02953561 |
| Azacitidine | Nivolumab | Phase II | Acute myeloid leukemia | ORR | NCT02397720 |
| Azacitidine | Gemtuzumab | Phase I/II | Acute myeloid leukemia | MTD | NCT00766116 |
| Azacitidine | R–CHOP | Phase I | Diffuse large B-cell lymphoma | MTD | NCT02343536 |
| Decitabine vorinostat | FLAG | Phase I | Acute myeloid leukemia | OS MTD ORR |
NCT02412475 |
| Chidamide Decitabine | CDCAG | Phase I/II | Acute myeloid leukemia | OS ORR |
NCT02886559 |
Note: OS, overall survival; EFS, event-free survival; ORR, objective remission rate; MTD, maximum tolerated dose; PFS, progression-free survival; R–CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; FLAG, fludarabine, cytarabine, and granulocyte colony-stimulating factor; CDCAG, aclarubicin, cytarabine, and granulocyte colony-stimulating factor.